Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Amevive Revival Strategy Includes Shorter Time To Reimbursement

Executive Summary

Biogen's strategy to meet its Amevive (alefacept) 2003 sales target includes increasing the physician referral rate and shortening the time needed for patients to secure reimbursement
Advertisement

Related Content

Elan Pinning 2005 Profitability Hopes On Antegren, Prialt Launches
Elan Pinning 2005 Profitability Hopes On Antegren, Prialt Launches
Biogen Wants To Reduce Amevive Copay, Adds Pharmacy Distribution
Genentech/Xoma Raptiva Clears FDA, Priced At 25% Discount to Amevive
Raptiva Manufacturing Issues Will Not Delay Approval, Launch – Genentech
Genentech Avastin Supply Will Come From Two Sites; BLA Coming Soon
Biogen Amevive Physician Reimbursement Guaranteed For Insurance Denials
Biogen Amevive Marketing Focus Will Be Duration Of Antipsoriatic Response
Biogen Amevive Marketing Focus Will Be Duration Of Antipsoriatic Response
Serono Rebif 25% Market Share Expected By 2006; Monthly Price Is $1,156
Advertisement
UsernamePublicRestriction

Register

PS042182

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel